Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Dyne Therapeutics, Inc. (Nasdaq:
DYN) announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share, generating expected gross proceeds of approximately $375.15 million before underwriting discounts and expenses.

The offering is expected to close on or about July 23, 2026, subject to customary closing conditions, and all shares are being sold by Dyne.

Dyne has also granted underwriters a 30‑day option to purchase up to an additional 2,745,000 shares at the same public offering price, less underwriting discounts and commissions.